Everything tagged "valuation" across research, earnings, and macro.
145 articles
DoorDash is evolving beyond food delivery into a broader local-commerce platform with strong revenue growth, rising profitability, and expanding membership scale. The stock still trades at premium multiples, but the business has crossed into durable cash generation.
Axsome has evolved into a commercial CNS growth story, led by AUVELITY’s rapid prescription gains and a newly expanded Alzheimer’s agitation opportunity. The stock looks attractive on execution, but valuation and ongoing losses keep it from being a low-risk idea.
Twist Bioscience is scaling revenue, expanding gross margin, and gaining traction in AI-enabled discovery, but the stock already prices in much of the progress. Our view is Hold as the company works toward profitability.
Roblox is still scaling fast, with Q1 2026 revenue up 39% and bookings up 43%, but safety-related changes have pressured guidance and keep the valuation debate alive. The platform’s expanding older-user mix and strong free cash flow support a Buy case despite execution risk.
Eli Lilly is delivering exceptional revenue and EPS growth, led by Mounjaro and Zepbound, while raising 2026 guidance again. The stock is expensive, but the franchise momentum and pipeline breadth keep the long-term case intact.
Palantir delivered 56% revenue growth, $1.63B in GAAP net income, and more than $2.1B in free cash flow in 2025, but the stock already prices in years of near-perfect execution. The business is exceptional, yet the valuation leaves limited room for error.
ServiceNow is still compounding at a high rate, with 20%+ revenue growth, expanding margins, and strong free cash flow. The report argues the stock remains a premium but attractive long-term platform play as AI deepens its workflow moat.
TSM remains a premier way to own AI infrastructure buildout, with 74% of wafer revenue from 7nm and below and HPC now 61% of sales. The stock looks attractive on durability and growth, though valuation and geopolitical risk keep it from being a no-brainer.
Intuitive Surgical is still compounding through mid-teens procedure growth, rising da Vinci 5 adoption, and a highly recurring revenue mix. The stock looks like a quality-growth name with strong execution, but valuation remains rich.
Astera Labs has surged on 115% revenue growth, strong margins, and real hyperscaler traction in AI infrastructure connectivity. The business looks excellent, but the stock trades at a premium that demands sustained execution.
Marvell is emerging as a key AI infrastructure supplier, with fiscal 2026 revenue up 42% and data center sales topping $6B. The upside is real, but the stock already prices in a lot of success at 36.4x forward earnings.
Netflix is still compounding like a premium growth platform, with 2025 revenue up 16%, margins expanding, and ad revenue scaling quickly. The stock looks attractive on pullbacks, but valuation remains rich and demands continued execution.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator